FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999684312> ?p ?o ?g. }

• W2999684312 endingPage "71" @default.
• W2999684312 startingPage "64" @default.
• W2999684312 abstract "Abstract Objectives SPECTRA is a multicenter, randomized phase II study of chemotherapy with cisplatin (CDDP) plus S-1 versus CDDP plus pemetrexed (PEM) in combination with thoracic radiotherapy (TRT) for locally advanced non-squamous non-small cell lung cancer, in order to determine which of these two regimens might be preferable for comparison with standard therapies in a future phase III study. Materials and methods Patients were randomly assigned to receive CDDP + S-1 (CDDP 60 mg/m2 on day 1 and S-1 80 mg/m2 on days 1–14, every 4 weeks, up to 4 cycles) or CDDP + PEM (CDDP 75 mg/m2 + PEM 500 mg/m2 on day 1, every 3 weeks, up to 4 cycles) combined with TRT (60 Gy in 30 fractions). The primary endpoint was the 2-year progression-free survival (PFS) rate. The sample size had been set at 100 patients. Results A total of 102 patients were randomized to receive CDDP + S-1 or CDDP + PEM (CDDP + S-1, n = 52; CDDP + PEM, n = 50) between January 2013 and October 2016. The results in the CDDP + S1 group and CDDP + PEM group were as follows: completion rates of TRT (60 Gy)/chemotherapy (4 cycles) was 92 %/73 % and 98 %/86 %, respectively; the response rates were 60 % and 64 %, respectively; median PFS after a median follow-up of 32.1 months, 12.7/13.8 months (hazard ratio [HR] = 1.16; 95 % confidence interval [CI], 0.73–1.84); 2-year PFS rate, 36.5 % (95 % CI, 23.5–49.6)/32.1 % (95 %CI, 18.9–45.4); median OS, 48.3/59.1 months (HR = 1.05; 95 %CI, 0.58–1.90); 2-year OS rate, 69.2 % (95 %CI, 56.7–81.8)/66.4 % (95 %CI, 53.0–79.9); Grade 3 toxicities: febrile neutropenia (12 %/2 %), anorexia (8 %/16 %), diarrhea (8 %/0 %), esophagitis (6 %/8 %), and neutropenia (35 %/50 %); Grade 2 or worse radiation pneumonitis, 15 % (8 patients)/4 % (2 patients). Conclusion The 2-year PFS rate in the CDDP + S-1 arm was higher than that in the CDDP + PEM arm. Both treatments were safe, with manageable toxicities." @default.
• W2999684312 created "2020-01-23" @default.
• W2999684312 creator A5003648443 @default.
• W2999684312 creator A5012542775 @default.
• W2999684312 creator A5030587345 @default.
• W2999684312 creator A5034276209 @default.
• W2999684312 creator A5037461196 @default.
• W2999684312 creator A5043607755 @default.
• W2999684312 creator A5063817865 @default.
• W2999684312 creator A5065387771 @default.
• W2999684312 creator A5066841617 @default.
• W2999684312 creator A5067259938 @default.
• W2999684312 creator A5074150160 @default.
• W2999684312 creator A5078287634 @default.
• W2999684312 creator A5086229141 @default.
• W2999684312 creator A5088647389 @default.
• W2999684312 creator A5090846902 @default.
• W2999684312 date "2020-03-01" @default.
• W2999684312 modified "2023-10-02" @default.
• W2999684312 title "Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study" @default.
• W2999684312 cites W2003863001 @default.
• W2999684312 cites W2005244154 @default.
• W2999684312 cites W2009771902 @default.
• W2999684312 cites W2017706312 @default.
• W2999684312 cites W2017813339 @default.
• W2999684312 cites W2019607817 @default.
• W2999684312 cites W2028621244 @default.
• W2999684312 cites W2033738330 @default.
• W2999684312 cites W2044374804 @default.
• W2999684312 cites W2063385579 @default.
• W2999684312 cites W2099725888 @default.
• W2999684312 cites W2102628344 @default.
• W2999684312 cites W2104347254 @default.
• W2999684312 cites W2112621029 @default.
• W2999684312 cites W2129675268 @default.
• W2999684312 cites W2134667653 @default.
• W2999684312 cites W2139939379 @default.
• W2999684312 cites W2145673038 @default.
• W2999684312 cites W2156353875 @default.
• W2999684312 cites W2160797118 @default.
• W2999684312 cites W2167191456 @default.
• W2999684312 cites W2198093519 @default.
• W2999684312 cites W2222151010 @default.
• W2999684312 cites W2263280562 @default.
• W2999684312 cites W2527905628 @default.
• W2999684312 cites W2561535902 @default.
• W2999684312 cites W2567564314 @default.
• W2999684312 cites W2753065806 @default.
• W2999684312 cites W2794288201 @default.
• W2999684312 cites W2796582438 @default.
• W2999684312 cites W2805354595 @default.
• W2999684312 cites W2890726357 @default.
• W2999684312 cites W2892640821 @default.
• W2999684312 cites W2893824814 @default.
• W2999684312 doi "https://doi.org/10.1016/j.lungcan.2020.01.008" @default.
• W2999684312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31955002" @default.
• W2999684312 hasPublicationYear "2020" @default.
• W2999684312 type Work @default.
• W2999684312 sameAs 2999684312 @default.
• W2999684312 citedByCount "11" @default.
• W2999684312 countsByYear W29996843122021 @default.
• W2999684312 countsByYear W29996843122022 @default.
• W2999684312 countsByYear W29996843122023 @default.
• W2999684312 crossrefType "journal-article" @default.
• W2999684312 hasAuthorship W2999684312A5003648443 @default.
• W2999684312 hasAuthorship W2999684312A5012542775 @default.
• W2999684312 hasAuthorship W2999684312A5030587345 @default.
• W2999684312 hasAuthorship W2999684312A5034276209 @default.
• W2999684312 hasAuthorship W2999684312A5037461196 @default.
• W2999684312 hasAuthorship W2999684312A5043607755 @default.
• W2999684312 hasAuthorship W2999684312A5063817865 @default.
• W2999684312 hasAuthorship W2999684312A5065387771 @default.
• W2999684312 hasAuthorship W2999684312A5066841617 @default.
• W2999684312 hasAuthorship W2999684312A5067259938 @default.
• W2999684312 hasAuthorship W2999684312A5074150160 @default.
• W2999684312 hasAuthorship W2999684312A5078287634 @default.
• W2999684312 hasAuthorship W2999684312A5086229141 @default.
• W2999684312 hasAuthorship W2999684312A5088647389 @default.
• W2999684312 hasAuthorship W2999684312A5090846902 @default.
• W2999684312 hasConcept C121608353 @default.
• W2999684312 hasConcept C126322002 @default.
• W2999684312 hasConcept C143998085 @default.
• W2999684312 hasConcept C168563851 @default.
• W2999684312 hasConcept C2776256026 @default.
• W2999684312 hasConcept C2776694085 @default.
• W2999684312 hasConcept C2777240266 @default.
• W2999684312 hasConcept C2778239845 @default.
• W2999684312 hasConcept C2778424827 @default.
• W2999684312 hasConcept C71924100 @default.
• W2999684312 hasConceptScore W2999684312C121608353 @default.
• W2999684312 hasConceptScore W2999684312C126322002 @default.
• W2999684312 hasConceptScore W2999684312C143998085 @default.
• W2999684312 hasConceptScore W2999684312C168563851 @default.
• W2999684312 hasConceptScore W2999684312C2776256026 @default.
• W2999684312 hasConceptScore W2999684312C2776694085 @default.
• W2999684312 hasConceptScore W2999684312C2777240266 @default.
• W2999684312 hasConceptScore W2999684312C2778239845 @default.
• W2999684312 hasConceptScore W2999684312C2778424827 @default.

• next